Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study

Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within...

Descripción completa

Detalles Bibliográficos
Autores: Hullekes, Frank, Buxeda, Anna, Pérez-Sáez, María José, Arias Cabrales, Carlos Enrique, Riella, Leonardo V.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/61255
Acceso en línea:http://hdl.handle.net/10230/61255
http://dx.doi.org/10.1016/j.ajt.2024.01.036
Access Level:acceso abierto
Palabra clave:Ronyons--Malalties
Ronyons--Trasplantació
id ES_3b67f0e6ebe4ee9a80976a9e8da705e3
oai_identifier_str oai:recercat.cat:10230/61255
network_acronym_str ES
network_name_str España
repository_id_str
spelling Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort studyHullekes, FrankBuxeda, AnnaPérez-Sáez, María JoséArias Cabrales, Carlos EnriqueRiella, Leonardo V.Ronyons--MalaltiesRonyons--TrasplantacióMembranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within the Post-Transplant Glomerular Disease Consortium, we conducted a retrospective multicenter cohort study examining the MN recurrence rate, risk factors, and response to treatment. This study screened 22,921 patients across 3 continents and included 194 patients who underwent a kidney transplant due to biopsy-proven MN. The cumulative incidence of MN recurrence was 31% at 10 years posttransplant. Patients with a faster progression toward end-stage kidney disease were at higher risk of developing recurrent MN (hazard ratio [HR], 0.55 per decade; 95% confidence interval [CI], 0.35-0.88). Moreover, elevated pretransplant levels of anti-phospholipase A2 receptor (PLA2R) antibodies were strongly associated with recurrence (HR, 18.58; 95% CI, 5.37-64.27). Patients receiving rituximab for MN recurrence had a higher likelihood of achieving remission than patients receiving renin-angiotensin-aldosterone system inhibition alone. In sum, MN recurs in one-third of patients posttransplant, and measurement of serum anti-PLA2R antibody levels shortly before transplant could aid in risk-stratifying patients for MN recurrence. Moreover, patients receiving rituximab had a higher rate of treatment response.Elsevier202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/61255http://dx.doi.org/10.1016/j.ajt.2024.01.036reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAm J Transplant. 2024 Jun;24(6):1016-26© 2024 The Authors. Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/612552026-05-29T05:05:01Z
dc.title.none.fl_str_mv Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
title Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
spellingShingle Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
Hullekes, Frank
Ronyons--Malalties
Ronyons--Trasplantació
title_short Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
title_full Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
title_fullStr Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
title_full_unstemmed Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
title_sort Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
dc.creator.none.fl_str_mv Hullekes, Frank
Buxeda, Anna
Pérez-Sáez, María José
Arias Cabrales, Carlos Enrique
Riella, Leonardo V.
author Hullekes, Frank
author_facet Hullekes, Frank
Buxeda, Anna
Pérez-Sáez, María José
Arias Cabrales, Carlos Enrique
Riella, Leonardo V.
author_role author
author2 Buxeda, Anna
Pérez-Sáez, María José
Arias Cabrales, Carlos Enrique
Riella, Leonardo V.
author2_role author
author
author
author
dc.subject.none.fl_str_mv Ronyons--Malalties
Ronyons--Trasplantació
topic Ronyons--Malalties
Ronyons--Trasplantació
description Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within the Post-Transplant Glomerular Disease Consortium, we conducted a retrospective multicenter cohort study examining the MN recurrence rate, risk factors, and response to treatment. This study screened 22,921 patients across 3 continents and included 194 patients who underwent a kidney transplant due to biopsy-proven MN. The cumulative incidence of MN recurrence was 31% at 10 years posttransplant. Patients with a faster progression toward end-stage kidney disease were at higher risk of developing recurrent MN (hazard ratio [HR], 0.55 per decade; 95% confidence interval [CI], 0.35-0.88). Moreover, elevated pretransplant levels of anti-phospholipase A2 receptor (PLA2R) antibodies were strongly associated with recurrence (HR, 18.58; 95% CI, 5.37-64.27). Patients receiving rituximab for MN recurrence had a higher likelihood of achieving remission than patients receiving renin-angiotensin-aldosterone system inhibition alone. In sum, MN recurs in one-third of patients posttransplant, and measurement of serum anti-PLA2R antibody levels shortly before transplant could aid in risk-stratifying patients for MN recurrence. Moreover, patients receiving rituximab had a higher rate of treatment response.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/61255
http://dx.doi.org/10.1016/j.ajt.2024.01.036
url http://hdl.handle.net/10230/61255
http://dx.doi.org/10.1016/j.ajt.2024.01.036
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Am J Transplant. 2024 Jun;24(6):1016-26
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406304204750848
score 15,81155

Similares en LA Referencia